Investors & Media

Press Releases

Date Title and Summary Additional Formats
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--May 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that in connection with the previously announced appointment of Isabel Kalofonos as ImmunoGen’s Chief
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and First Quarter 2023 Financial Results
Strong Adoption of ELAHERE; Net Sales of $29.5 Million in First Full Quarter of Launch Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Early May; Expected to Support Full Approval of ELAHERE in the US and Expansion into Europe Announced Non-Dilutive Financing for Up to $175 Million
View HTML
Toggle Summary ImmunoGen Appoints Isabel Kalofonos as Senior Vice President and Chief Commercial Officer
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 24, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that Isabel Kalofonos has been appointed Senior Vice President and Chief Commercial Officer.
View HTML
Toggle Summary ImmunoGen Announces Conference Call to Discuss Its First Quarter 2023 Operating Results
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 13, 2023-- ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, April 28, 2023 to discuss its
View HTML
Toggle Summary ImmunoGen Announces Non-Dilutive Term Loan Financing for Up to $175 Million with Pharmakon Advisors
ImmunoGen to Receive $75 Million Upon Execution of the Agreement; Eligible to Receive up to an Additional $100 Million in Near-Term Proceeds WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 6, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Apr. 3, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on March 31, 2023 , the Compensation Committee of the Company’s Board of Directors approved, in
View HTML
Toggle Summary ImmunoGen Presents Final Overall Survival and Additional Efficacy Data from the SORAYA Trial at SGO Annual Meeting
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 25, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced final overall survival data and an evaluation of sequence of therapy in the pivotal SORAYA trial of
View HTML
Toggle Summary ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. , (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on February 28, 2023 , the Compensation Committee of the Company’s Board of Directors approved, in
View HTML
Toggle Summary ImmunoGen Reports Recent Progress and 2022 Financial Results
Launched ELAHERE™ (mirvetuximab soravtansine-gynx), the First and Only ADC Approved for Platinum-Resistant Ovarian Cancer in the US; ELAHERE Monotherapy and in Combination with Bevacizumab Included in NCCN Guidelines and Compendium Top-Line Results from Confirmatory MIRASOL Trial Anticipated in Q2
View HTML
Toggle Summary ImmunoGen Announces a Global, Multi-Target License and Option Agreement with Vertex for the Use of ImmunoGen's ADC Technology in the Development of Novel Targeted Conditioning Agents
ImmunoGen to Receive a $15 Million Upfront Payment; Eligible to Receive Up to $337 Million in Potential Option Fees and Milestone Payments Plus Tiered Royalties on a Per Target Basis WALTHAM, Mass. --(BUSINESS WIRE)--Mar. 1, 2023-- ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of
View HTML